Under the agreement, Beactica will use its proprietary drug discovery platform, Sprint, to generate small-molecule lead compounds against undisclosed targets of therapeutic interest to Janssen.
Reportedly, Janssen is the fourth global pharmaceutical company to enter into an agreement with Beactica over the past one and half years.
Beactica CEO Per Kallblad said fragment-based approaches to drug discovery are creating new pathways towards small-molecule leads of high-quality.